Lung Transplant Coagulopathy Management Protocol

Patient selection and eligibility criteria for the current secondary analysis mirrored that of the Point of Care Management of Coagulopathy in Lung Transplantation trial and included patients who underwent LuTx at the University Hospital Motol between January 2018 and June 2020 [18 (link)]. The exclusion criteria were electively prolonged postoperative ECMO (patients with idiopathic pulmonary hypertension or preoperatively known severe secondary pulmonary hypertension on basis of underlying disease that were preoperatively identified to require intended ECMO prolongation leading automatically to classification as PGD grade 3, as this would result in negative impact on interpretation of the study), pediatric recipients, single-lung transplantations, retransplantations, heart–lung transplantations, and transplantations requiring cardiopulmonary bypass for technical reasons (concomitant cardiac surgery).
Randomization and detailed description of two randomized groups were described previously [18 (link)]. In the first group (POC group), 31 patients were analyzed, and in the second group (non-POC group), 36 patients were analyzed. A flow diagram based on the Consolidated Standards of Reporting Trials (CONSORT) is displayed in Fig. 2.Fig. 2

Flow chart of the study population